Third Expansion of IDEXX's Catalyst Platform in Under a Year Delivers Critical Insights to Veterinarians Evaluating Canine Patients for Endocrine Disorders

Rhea-AI Summary

IDEXX Laboratories (NASDAQ: IDXX) has launched the Catalyst Cortisol Test, marking the third expansion of its Catalyst platform in under a year. This innovative test measures real-time cortisol concentrations in dogs to aid in diagnosing Addison's disease and Cushing's syndrome. The test provides point-of-care diagnostic capabilities with accuracy comparable to IDEXX Reference Laboratories. Key features include interpretive guidance through integration with IDEXX Vetlab Station and VetConnect PLUS, and an efficient load-and-go workflow. The test will launch in the U.S. and Canada by July 2025, followed by a global rollout to over 75,000 Catalyst chemistry analyzers starting Q3 2025. This development enhances veterinarians' ability to diagnose and treat life-threatening endocrine disorders during patient visits, particularly benefiting cases of Addison's disease, which is notoriously difficult to diagnose, and Cushing's syndrome, which requires long-term management.

Positive

• Third platform expansion in under a year demonstrates strong R&D execution and innovation pipeline
• Large addressable market with installation base of over 75,000 Catalyst chemistry analyzers globally
• Test provides new revenue stream through diagnostic capabilities for common canine endocrine disorders
• Integration with existing IDEXX systems enhances product ecosystem and customer retention

Negative

• None.

Insights

Veterinary Medical Technology Analyst

IDEXX's new Catalyst Cortisol Test significantly enhances point-of-care diagnostics for critical canine endocrine disorders, strengthening their market position.

IDEXX has launched the Catalyst Cortisol Test, marking the third expansion of their Catalyst platform in less than a year. This strategic addition addresses a critical diagnostic need in veterinary medicine by enabling point-of-care testing for canine Addison's disease and Cushing's syndrome - two challenging endocrine disorders with significant health implications.

The clinical value proposition is compelling. Addison's disease, often called "the great pretender," is difficult to diagnose due to its nonspecific symptoms that mimic other conditions. Early detection is literally lifesaving. Meanwhile, Cushing's syndrome requires ongoing management, and untreated cases significantly diminish quality of life in affected dogs. By bringing cortisol testing in-house, IDEXX allows veterinarians to diagnose and begin treatment within a single visit - a substantial workflow improvement over traditional reference lab testing.

From a market perspective, this launch strengthens IDEXX's competitive position in the point-of-care diagnostics space by expanding the capabilities of their 75,000+ installed Catalyst analyzers worldwide. The company is executing a clear strategy of continually enhancing the value proposition of their installed base through menu expansion, effectively increasing the utility of existing devices while creating additional recurring revenue streams through proprietary test sales.

The phased rollout strategy - starting with the US and Canada in July 2025 followed by global expansion in Q3 2025 - allows IDEXX to manage the launch effectively while capturing revenue in their highest-value markets first. This approach to platform enhancement exemplifies IDEXX's "Technology for Life" value proposition, where installed instruments gain capabilities over time, reinforcing customer loyalty and reducing competitive switching.

The Catalyst^® Cortisol Test provides veterinarians with real-time critical insights when evaluating dogs for Addison's disease and Cushing's syndrome

WESTBROOK, Maine, June 5, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst^® Cortisol Test, which measures real-time quantitative cortisol concentrations to support the diagnosis of Addison's disease and diagnosis and management of Cushing's syndrome in dogs. IDEXX's Catalyst Cortisol Test is the third menu expansion in under a year for the Catalyst platform, further advancing the diagnostic capabilities available to veterinary practices at the point-of-care.

Addison's disease, often called "the great pretender," is a life-threatening condition caused by low cortisol and is difficult to diagnose due to its common and nonspecific clinical signs that can resemble those of other illnesses, such as gastroenteritis or kidney disease. Early detection is critical, as timely treatment can be lifesaving. Cushing's syndrome, driven by excess cortisol, is a common endocrine disorder in older dogs, and certain breeds are at an increased risk. Cushing's syndrome requires long-term management, and if left untreated, it can significantly diminish quality of life.

IDEXX's Catalyst Cortisol Test enables veterinarians to confidently and accurately diagnose or rule out Addison's disease and Cushing's syndrome during the patient visit, allowing for immediate treatment or adjustments to ongoing care management. This workflow efficiency continues throughout the patient journey with monitoring capabilities that enable tailored treatment adjustments, improving long-term care for patients with Cushing's syndrome.

"The Catalyst Cortisol Test is an accurate and highly requested test that addresses a critical need for our customers and equips veterinarians with built-in results interpretation for prompt action, supporting better health outcomes for dogs," said Jay Mazelsky, President and Chief Executive Officer of IDEXX. "Continuing to expand the Catalyst platform reinforces our Technology for Life promise, offering our customers solutions that advance in capabilities over time to expand clinical insights and care delivery at the point-of-care."

The IDEXX Catalyst Cortisol Test features:

• Accuracy: Provides quantitative results in-clinic that align with IDEXX Reference Laboratories, enabling veterinarians to confidently diagnose or rule out Addison's disease and Cushing's syndrome.
• Interpretive guidance: Integrates with the IDEXX Vetlab^® Station and VetConnect^® PLUS, providing results-specific interpretation in real-time during the patient visit.
• Efficiency: The Catalyst Cortisol Test's load-and-go workflow can run alone or with additional chemistry tests using a single sample for comprehensive diagnostic insights into patient health status. This workflow saves hands-on sample preparation time for veterinary technicians and ensures repeatable results.

"A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs," said Patty Lathan, VMD, MS, DACVIM (SAIM).* "Additionally, by delivering accurate results during the visit, it supports timely care and streamlines daily workflows for busy veterinary teams."

The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025, with a global rollout to the installed base of more than 75,000 Catalyst chemistry analyzers expected to start in the third quarter of 2025. For more information, visit the IDEXX Catalyst test menu web page.

About IDEXX
IDEXX Laboratories, Inc., is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," "project," and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov and via IDEXX's website at idexx.com).

*Dr. Lathan has received compensation for consulting services she has provided to IDEXX from time to time.

View original content to download multimedia:https://www.prnewswire.com/news-releases/third-expansion-of-idexxs-catalyst-platform-in-under-a-year-delivers-critical-insights-to-veterinarians-evaluating-canine-patients-for-endocrine-disorders-302472370.html

SOURCE IDEXX Laboratories, Inc.

FAQ

When will IDEXX's new Catalyst Cortisol Test be available in the US and Canada?

The Catalyst Cortisol Test will be available in the U.S. and Canada at the end of July 2025.

What conditions can IDEXX's new Catalyst Cortisol Test diagnose in dogs?

The test can diagnose and help manage both Addison's disease and Cushing's syndrome in dogs by measuring real-time cortisol concentrations.

How many Catalyst chemistry analyzers does IDEXX have installed globally?

IDEXX has an installed base of more than 75,000 Catalyst chemistry analyzers globally.

What are the key features of IDEXX's new Catalyst Cortisol Test?

The test features accuracy aligned with IDEXX Reference Laboratories, interpretive guidance through integration with IDEXX systems, and an efficient load-and-go workflow that can run alone or with other chemistry tests.

How many platform expansions has IDEXX's Catalyst platform had in the past year?

This is the third expansion of IDEXX's Catalyst platform in under a year.